Sign up to access all valuation multiples
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and sells injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. Its products focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: North America (NA) and Europe & Rest of the World (EUROW).
1999
127
LTM Revenue $123M
LTM EBITDA $24.4M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of November 2025, BoneSupport reported last 12-month revenue of $123M and EBITDA of $24.4M.
In the same period, BoneSupport generated $114M in LTM gross profit and $17.0M in net income.
See BoneSupport valuation multiples based on analyst estimatesIn the most recent fiscal year, BoneSupport reported revenue of $95.2M and EBITDA of $19.7M.
BoneSupport expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BoneSupport valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $123M | XXX | $95.2M | XXX | XXX | XXX |
| Gross Profit | $114M | XXX | $88.1M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $24.4M | XXX | $19.7M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $24.2M | XXX | $15.6M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $17.0M | XXX | $14.2M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BoneSupport has current market cap of SEK 12.6B (or $1.3B), and EV of SEK 12.3B (or $1.3B).
As of December 3, 2025, BoneSupport's stock price is SEK 192 (or $20).
See BoneSupport trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.3B | XXX | XXX | XXX | XXX | $0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialBoneSupport's trades at 13.7x EV/Revenue multiple, and 66.1x EV/EBITDA.
See valuation multiples for BoneSupport and 15K+ public compsAs of December 3, 2025, BoneSupport has market cap of $1.3B and EV of $1.3B.
Equity research analysts estimate BoneSupport's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BoneSupport has a P/E ratio of 78.8x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | 13.7x | XXX | XXX | XXX |
| EV/EBITDA | 53.3x | XXX | 66.1x | XXX | XXX | XXX |
| EV/EBIT | 53.7x | XXX | 83.1x | XXX | XXX | XXX |
| EV/Gross Profit | 11.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 78.8x | XXX | 94.5x | XXX | XXX | XXX |
| EV/FCF | 65.8x | XXX | 204.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBoneSupport's last 12 month revenue growth is 33%
BoneSupport's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.6M for the same period.
BoneSupport's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BoneSupport's rule of X is 102% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BoneSupport and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 87% | XXX | 185% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 54% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 102% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BoneSupport acquired XXX companies to date.
Last acquisition by BoneSupport was XXXXXXXX, XXXXX XXXXX XXXXXX . BoneSupport acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was BoneSupport founded? | BoneSupport was founded in 1999. |
| Where is BoneSupport headquartered? | BoneSupport is headquartered in Sweden. |
| How many employees does BoneSupport have? | As of today, BoneSupport has 127 employees. |
| Who is the CEO of BoneSupport? | BoneSupport's CEO is Mr. Emil Billback. |
| Is BoneSupport publicy listed? | Yes, BoneSupport is a public company listed on STO. |
| What is the stock symbol of BoneSupport? | BoneSupport trades under BONEX ticker. |
| When did BoneSupport go public? | BoneSupport went public in 2017. |
| Who are competitors of BoneSupport? | Similar companies to BoneSupport include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of BoneSupport? | BoneSupport's current market cap is $1.3B |
| What is the current revenue of BoneSupport? | BoneSupport's last 12 months revenue is $123M. |
| What is the current revenue growth of BoneSupport? | BoneSupport revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of BoneSupport? | Current revenue multiple of BoneSupport is 10.6x. |
| Is BoneSupport profitable? | Yes, BoneSupport is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BoneSupport? | BoneSupport's last 12 months EBITDA is $24.4M. |
| What is BoneSupport's EBITDA margin? | BoneSupport's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of BoneSupport? | Current EBITDA multiple of BoneSupport is 53.3x. |
| What is the current FCF of BoneSupport? | BoneSupport's last 12 months FCF is $19.8M. |
| What is BoneSupport's FCF margin? | BoneSupport's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of BoneSupport? | Current FCF multiple of BoneSupport is 65.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
